Y-F Zhao1, L Li, H-J Li, F-R Yang, Z-K Liu, X-W Hu, Q Wang. 1. Department of Oncology, The Affiliated Hospital of Shandong University of TCM, Jinan, China. 2020100080@sdutcm.edu.cn.
Abstract
OBJECTIVE: The purpose of this study was to explore the expression pattern of long non-coding RNA (lncRNA) ZFPM2-AS1 in breast cancer (BC) tissues, and its biological influence on clinical features and prognosis in BC patients. PATIENTS AND METHODS: ZFPM2-AS1 levels in 52 paired BC tissues and adjacent normal ones were detected. Then, the relationship between ZFPM2-AS1 level and clinical features in BC patients was analyzed. Regulatory effects of ZFPM2-AS1 on proliferative and migratory abilities in MCF-7 and SKBR3 cells were assessed. In addition, in vivo regulation of ZFPM2-AS1 in nude mice bearing BC was evaluated. Finally, the interaction between ZFPM2-AS1 and JMJD6 and the involvement of ZFPM2-AS1 in the development of BC were illustrated. RESULTS: The results showed that ZFPM2-AS1 was upregulated in BC tissues, and its high level was linked to advanced tumor stage, high rates of lymphatic metastasis, and distant metastasis, as well as poor prognosis in BC. The knockdown of ZFPM2-AS1 suppressed proliferative and migratory abilities in BC cells. In addition, JMJD6 was verified to be the downstream gene binding to ZFPM2-AS1, which was highly expressed in BC tissues and positively regulated by ZFPM2-AS1. In vivo knockdown of ZFPM2-AS1 in nude mice bearing BC showed a smaller tumor volume and lower tumor weight than controls. In addition, JMJD6 was downregulated in BC tumors extracted from mice with silenced ZFPM2-AS1. CONCLUSIONS: LncRNA ZFPM2-AS1 is upregulated in BC and linked to tumor stage, metastasis, and prognosis in BC patients. It aggravates the malignant development of BC via upregulating JMJD6.
OBJECTIVE: The purpose of this study was to explore the expression pattern of long non-coding RNA (lncRNA) ZFPM2-AS1 in breast cancer (BC) tissues, and its biological influence on clinical features and prognosis in BC patients. PATIENTS AND METHODS: ZFPM2-AS1 levels in 52 paired BC tissues and adjacent normal ones were detected. Then, the relationship between ZFPM2-AS1 level and clinical features in BC patients was analyzed. Regulatory effects of ZFPM2-AS1 on proliferative and migratory abilities in MCF-7 and SKBR3 cells were assessed. In addition, in vivo regulation of ZFPM2-AS1 in nude mice bearing BC was evaluated. Finally, the interaction between ZFPM2-AS1 and JMJD6 and the involvement of ZFPM2-AS1 in the development of BC were illustrated. RESULTS: The results showed that ZFPM2-AS1 was upregulated in BC tissues, and its high level was linked to advanced tumor stage, high rates of lymphatic metastasis, and distant metastasis, as well as poor prognosis in BC. The knockdown of ZFPM2-AS1 suppressed proliferative and migratory abilities in BC cells. In addition, JMJD6 was verified to be the downstream gene binding to ZFPM2-AS1, which was highly expressed in BC tissues and positively regulated by ZFPM2-AS1. In vivo knockdown of ZFPM2-AS1 in nude mice bearing BC showed a smaller tumor volume and lower tumor weight than controls. In addition, JMJD6 was downregulated in BC tumors extracted from mice with silenced ZFPM2-AS1. CONCLUSIONS: LncRNA ZFPM2-AS1 is upregulated in BC and linked to tumor stage, metastasis, and prognosis in BC patients. It aggravates the malignant development of BC via upregulating JMJD6.